Caroline Seymour


Ibrutinib Boosts the Activity of Second CD19-Directed CAR T-Cell Therapy in Refractory Non-Hodgkin Lymphoma

May 14, 2021

A second treatment with CD19-directed CAR T-cell therapy plus ibrutinib (Imbruvica) following failed prior CD19-directed CAR T-cell therapy and salvage treatment with ibrutinib led to greater efficiency and anti-CD19 CAR T-cell amplification, but also higher grades of cytokine release syndrome and more serious hematologic toxicity in patients with refractory B-cell non-Hodgkin lymphoma.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

February 25, 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.